Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisinicline for smoking cessation
NCT04576949Phase 3Completed
- Sponsor
- Achieve Life Sciences
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Tobacco Use Disorder (TUD) comparing Placebo + Behavioral Support, Cytisinicline 6 weeks + Placebo + Behavioral Support and Cytisinicline 12 weeks + Behavioral Support (3 arms). Primary endpoints: Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6 and Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12. Started Oct 2020; status: completed.
02
Drugs
cytisinicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT04576949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576949.